Professional development Vacancies

Regarding amendments to the instructions for medical use of medicinal products containing carbamazepine (carbamazepine)

08.11.2021 1969 views

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the evaluation of the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing carbamazepine (carbamazepine), drew the following conclusions:

Interaction with brivaracetam (brivaracetam)

Given the available data on the interaction with brivaracetam from the literature and the information included in the instructions for medical use of medicinal products containing brivaracetam, the PRAC concluded that the instructions for medical use of medicinal products containing carbamazepine should be updated to reflect the interaction between carbamazepine and brivaracetam

Hyperammonemia

Given the available data on hyperammonemia from the literature and spontaneous reports, including, in some cases, the absence of a relevant history, a plausible time to onset, a case with a positive test for re-administration and repeated discontinuation (de-challenge) and/or a case with a positive test for re-prescription (re-challenge), PRAC considers that a causal relationship between the use of carbamazepine and the occurrence of hyperammonemia is at least possible. PRAC concluded that the instructions for medical use of medicinal products containing carbamazepine should be amended accordingly.

Use during pregnancy and in women of reproductive age

Given the available data on use during pregnancy and in women of childbearing age from the literature, non-interventional studies (including registries), and spontaneous reports, PRAC concluded that the instructions for medical use of medicinal products containing carbamazepine that do not have similar wording should be amended to add information on the risks associated with use during pregnancy, the need for effective contraception and counseling in women of childbearing age, and the possibility of interaction with hormonal contraception, which could potentially lead to insufficient efficacy.

The Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) agrees with the scientific conclusions of the PRAC.

Based on the scientific conclusions on carbamazepine, the CMDh considers that the benefit/risk balance of medicinal products containing carbamazepine remains unchanged, provided that amendments are made to the instructions for medical use.

Amendments to be included in the relevant sections of the package insert (new text underlined in bold, deleted text struck through).

Section “Special warnings and precautions for use”

The information should be included or updated as follows:

Women of reproductive age

Carbamazepine may cause fetal harm when used by a pregnant woman. Prenatal exposure to carbamazepine may increase the risk of major congenital malformations and other adverse developmental outcomes (see section “Use during pregnancy or breastfeeding. Pregnancy. Breastfeeding. Fertility”).

Unless, after careful consideration of alternative treatment options, the benefit is judged to outweigh the risks, carbamazepine (carbamazepine) should not be used in women of childbearing potential.

Women of reproductive age must be fully informed about the potential risk to the fetus if they take carbamazepine during pregnancy.

Before starting treatment with carbamazepine, the possibility of performing a pregnancy test should be considered for women of childbearing age.

Women of reproductive age must use effective contraception during treatment and for two weeks after treatment discontinuation. Due to enzyme induction, carbamazepine may impair the therapeutic effect of hormonal contraceptives; therefore, women of childbearing potential should be advised to consult regarding the use of other effective methods of contraception (see sections “Interaction with other medicinal products and other forms of interaction” and “Use during pregnancy or breastfeeding. Pregnancy. Breastfeeding. Fertility”).

Women of reproductive age should consult a doctor as soon as they plan a pregnancy, to discuss switching to alternative treatment before conception and before discontinuing contraception (see section “Use during pregnancy or breastfeeding. Pregnancy. Breastfeeding. Fertility”).

Women of reproductive age should be advised to see a doctor immediately if they become pregnant or think they may be pregnant while taking carbamazepine.

Section “Interaction with other medicinal products and other forms of interaction”

The interaction section should be changed as follows:

Agents that may increase the plasma level of the active metabolite of carbamazepine, carbamazepine-10, 11-epoxide

Since an increase in the plasma level of carbamazepine-10,11-epoxide may lead to adverse reactions (for example, dizziness, drowsiness, ataxia, diplopia), the dose of [carbamazepine or name of the medicinal product] should be adjusted accordingly and/or its plasma level should be monitored when co-administered with the substances described below:

Antiepileptic drugs: progabide, valproic acid, valnoctamide, valpromide, primidone, brivaracetam.

Section “Use during pregnancy or breastfeeding. Pregnancy. Breastfeeding. Fertility”

The information should be included or updated as follows:

Pregnancy

General risk associated with the use of antiepileptic medicinal products (AEMPs)

All women of reproductive age who are taking antiepileptic therapy, and especially women planning a pregnancy and pregnant women, should be given medical advice about the potential risk to the fetus caused by both seizures and antiepileptic treatment.

Abrupt discontinuation of treatment with antiepileptic medicinal products should be avoided, as this may lead to seizures, which can have serious consequences for the woman and the unborn child.

Where possible, monotherapy is preferred for the treatment of epilepsy during pregnancy, since therapy with multiple antiepileptic medicinal products may be associated with a higher risk of congenital malformations.

Risks associated with carbamazepine (carbamazepine)

Carbamazepine crosses the placental barrier. Prenatal exposure to carbamazepine may increase the risk of congenital malformations and other adverse developmental outcomes. Exposure to carbamazepine during pregnancy is associated with a frequency of major malformations 2–3 times higher than in the general population, in which the frequency is 2–3%. Malformations such as fetal neural tube defects, craniofacial defects such as cleft lip/palate, cardiovascular malformations, hypospadias, digit hypoplasia, and other anomalies affecting various systems of the fetal body have been reported in mothers who used carbamazepine during pregnancy. Specialized antenatal monitoring for these malformations is recommended. Neurodevelopmental disorders have been reported among children born to women with epilepsy who used carbamazepine during pregnancy, alone or in combination with other antiepileptic medicinal products. Studies on the risk of developing nervous system disorders in children who received carbamazepine during pregnancy are contradictory, and the risk cannot be ruled out.

Unless, after careful consideration of alternative treatment options, the benefit is judged to outweigh the risks, carbamazepine (carbamazepine) should not be used in women during pregnancy. The woman must be fully informed and understand the risks of taking carbamazepine (carbamazepine) during pregnancy.

Data indicate that the risk of malformations with the use of carbamazepine may be dose-dependent. If, based on a careful benefit/risk assessment, an alternative treatment is not suitable and treatment with carbamazepine is continued, monotherapy and the lowest effective dose of carbamazepine should be used and monitoring of plasma levels is recommended. The plasma concentration can be maintained in the lower part of the therapeutic range of 4 to 12 µg/mL, provided that seizure control is maintained.

It has been reported that some antiepileptic medicinal products, such as carbamazepine, reduce serum folate levels. This deficiency may contribute to an increased incidence of congenital malformations in the fetus of a mother with epilepsy. Folic acid is recommended before and during pregnancy. To prevent coagulation disorders in the child, it is also recommended to give vitamin K1 to the mother during the last weeks of pregnancy, as well as to newborns.

If a woman is planning a pregnancy, every effort should be made, before conception and before stopping contraception, to switch to an appropriate alternative treatment. If a woman becomes pregnant while taking carbamazepine, she should be referred to a specialist to reassess the treatment method and consider alternative options.

Women of reproductive age

Carbamazepine should not be used in women of childbearing potential, except in cases where the potential benefit/risk outweighs alternative treatment options. The woman must be fully informed and understand the potential risk to the fetus when taking carbamazepine during pregnancy, therefore it is important to plan the pregnancy in advance. Before starting treatment with carbamazepine, the possibility of performing a pregnancy test in women of childbearing potential should be considered.

Women of childbearing potential must use effective contraception during treatment and for two weeks after its discontinuation. Due to enzyme induction, carbamazepine may impair the therapeutic effect of hormonal contraceptives (see section “Interaction with other medicinal products and other forms of interaction”), therefore women of childbearing potential should be advised to consult about the use of other effective methods of contraception. At least one effective method of contraception (for example, an intrauterine method) or two complementary forms of contraception, including a barrier method, should be used. When choosing a method of contraception, individual circumstances should be assessed, involving the patient in the discussion.

“Adverse reactions” section

The adverse reaction Hyperammonemia should be added to the section “Metabolism and nutrition disorders” with the frequency “Not known”

Перелік лікарських засобів, що містять карбамазепін (carbamazepine) і дозволені до медичного застосування в Україні (за даними Державного реєстру лікарських засобів України станом на 03.11.2021).

To analyze the published information, the applicant must use the original text available at the link https://www.ema.europa.eu/en/documents/psusa/carbamazepine-scientific-conclusions-grounds-variation-terms-marketing-authorisation-psusa-00000539_en.pdf